Literature DB >> 28944097

Prevalence and Clinical Characteristics of Rheumatoid Arthritis in an Inner City Population with Sickle Cell Disease.

Isabel M McFarlane1, David J Ozeri1, Joshy Pathiparampil1, Randolph Sanchez1, Justin Levinson1, Odeth Barrett-Campbell1, Carla Saladini-Aponte1, Beatrix Boisette1, Moro Salifu1.   

Abstract

OBJECTIVES: Rheumatoid arthritis (RA) has been rarely reported in association with sickle cell disease (SCD). Our study aimed to estimate the prevalence of RA in SCD population and to describe the clinical characteristics of RA associated with SCD.
METHODS: Retrospective chart review of SCD and RA patients followed at 2 large urban hospitals. Seven RA/SCD patients were identified and compared to age and sex matched cohort of SCD only and of RA only group. All patients were Black.
RESULTS: There were 739 SCD cases, seven (0.94%) met ACR criteria for RA (SCD-RA), 411 cases were RA only group. Mean age was significantly higher in SCD-RA compared to the entire population of SCD and RA (41.7 ± 3.9 (± SEM) vs. 33.26 ± 0.47, vs. 61.39 ± 0.79, p<0.01). SCD-RA patients had lower hemoglobin (g/dl) when compared to the age and sex matched SCD or RA only patients (7.4 ± 0.49 vs. 8.3 ± 0.60 vs. 11 ± 0.59, p <0.01) respectively. There were no significant differences in laboratory and treatment approach between SCD-RA and RA only groups, except for the radiographic evidence of periarticular osteopenia and greater difficulty in the activities of daily living (ADL) among SCD-RA cohort, compared to the age and sex matched RA cohort (p=0.01).
CONCLUSION: In contrast to older reports, the prevalence of RA among SCD patients in our study (0.94%) was similar to that reported in the general population (0.5-1%) and was to be associated with difficulty in ADL and periarticular osteopenia. Since RA manifests at an older age, our reported prevalence is likely explainable by improved survival of SCD patients due to enhanced medical care and the advent of hydroxyurea as a major therapeutic breakthrough for SCD.

Entities:  

Keywords:  Clinical characteristics; Rheumatoid arthritis; Sickle cell disease; Vaso-occlusive crises; prevalence

Year:  2017        PMID: 28944097      PMCID: PMC5609465          DOI: 10.4172/2329-8731.1000218

Source DB:  PubMed          Journal:  Rheumatology (Sunnyvale)


  22 in total

1.  Epinephrine modulates BCAM/Lu and ICAM-4 expression on the sickle cell trait red blood cell membrane.

Authors:  Jamie L Maciaszek; Biree Andemariam; Greg Huber; George Lykotrafitis
Journal:  Biophys J       Date:  2012-03-06       Impact factor: 4.033

2.  2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker
Journal:  Arthritis Rheum       Date:  2010-09

3.  Rheumatoid arthritis in a patient with sickle cell disease.

Authors:  C Marino; E McDonald
Journal:  J Rheumatol       Date:  1990-07       Impact factor: 4.666

Review 4.  Sickle-cell disease.

Authors:  David C Rees; Thomas N Williams; Mark T Gladwin
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

Review 5.  Epidemiology of adult rheumatoid arthritis.

Authors:  Yannis Alamanos; Alexandros A Drosos
Journal:  Autoimmun Rev       Date:  2005-03       Impact factor: 9.754

6.  The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

Authors:  Martin H Steinberg; William F McCarthy; Oswaldo Castro; Samir K Ballas; F Danny Armstrong; Wally Smith; Kenneth Ataga; Paul Swerdlow; Abdullah Kutlar; Laura DeCastro; Myron A Waclawiw
Journal:  Am J Hematol       Date:  2010-06       Impact factor: 10.047

7.  Neutrophil sandwiches injure the microcirculation.

Authors:  Mark R Looney; Michael A Matthay
Journal:  Nat Med       Date:  2009-04       Impact factor: 53.440

Review 8.  Hemostatic abnormalities in sickle cell disease.

Authors:  Ming Y Lim; Kenneth I Ataga; Nigel S Key
Journal:  Curr Opin Hematol       Date:  2013-09       Impact factor: 3.284

Review 9.  Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins.

Authors:  Dominik J Schaer; Paul W Buehler; Abdu I Alayash; John D Belcher; Gregory M Vercellotti
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

10.  Non-gouty arthritis in sickle cell disease: report of 37 consecutive cases.

Authors:  K de Ceulaer; M Forbes; D Roper; G R Serjeant
Journal:  Ann Rheum Dis       Date:  1984-08       Impact factor: 19.103

View more
  3 in total

1.  Impact of vitamin D deficiency on clinical parameters in treatment-naïve rheumatoid arthritis patients.

Authors:  Yang Liu; Hongyan Wen
Journal:  Z Rheumatol       Date:  2018-11       Impact factor: 1.372

Review 2.  Rheumatic Manifestations of Haemoglobinopathies.

Authors:  Michael Hughes
Journal:  Curr Rheumatol Rep       Date:  2018-08-14       Impact factor: 4.592

3.  Rheumatoid Arthritis in Sickle-Cell Population: Pathophysiologic Insights, Clinical Evaluation and Management.

Authors:  Isabel M McFarlane; David J Ozeri; Yair Saperstein; Milena Rodriguez Alvarez; Su Zhaz Leon; Kristaq Koci; Sophia Francis; Soberjot Singh; Moro Salifu
Journal:  Rheumatology (Sunnyvale)       Date:  2017-09-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.